{
  "image_filename": "table_p7_det_6_004.png",
  "image_path": "Hsiao_et_al.__2023_/extracted/figures/table_p7_det_6_004.png",
  "image_type": "Table",
  "page_number": 7,
  "block_id": "det_6_004",
  "claim_id": "claim_003",
  "claim": "Recombinant technology leads to a broader immune response that may provide cross-protection, even in a mismatch season.",
  "supports_claim": false,
  "explanation": "A baseline characteristics table showing numbers and percentages of participants in two vaccine groups (recombinant vaccine and inactivated vaccine) and overall: age distribution, sex, race/ethnic group, presence of underlying illnesses (asthma, diabetes, COPD, heart disease), and history of influenza vaccination in the previous year. This demographic table presents participant characteristics and does not include any data on immune response breadth, cross-protection, or mismatch-season effectiveness, and therefore does not support the claim. Note: Table only shows baseline demographics; no immunogenicity or effectiveness outcomes are reported in this excerpt.",
  "model_used": "o4-mini",
  "detailed_analysis": {
    "supports_claim": false,
    "image_description": "A baseline characteristics table showing numbers and percentages of participants in two vaccine groups (recombinant vaccine and inactivated vaccine) and overall: age distribution, sex, race/ethnic group, presence of underlying illnesses (asthma, diabetes, COPD, heart disease), and history of influenza vaccination in the previous year.",
    "evidence_found": null,
    "reasoning": "This demographic table presents participant characteristics and does not include any data on immune response breadth, cross-protection, or mismatch-season effectiveness, and therefore does not support the claim.",
    "confidence_notes": "Table only shows baseline demographics; no immunogenicity or effectiveness outcomes are reported in this excerpt."
  }
}